|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||27.51 - 27.80|
|52 Week Range||26.30 - 32.82|
|PE Ratio (TTM)||22.07|
|Forward Dividend & Yield||1.08 (4.10%)|
|1y Target Est||N/A|
OTCQX: RHHBY) today announced that Sophie Kornowski-Bonnet, Head of Roche Partnering and member of the enlarged Corporate Executive Committee since 2012, has accepted a new opportunity and will be leaving the company effective 31 July 2018. James Sabry, MD, PhD, currently Head of Partnering for Genentech Research and Early Development (gRED), has been appointed Global Head of Partnering, a role that combines the partnering functions across the Roche pharmaceuticals business, and will become a member of the enlarged Corporate Executive Committee. Roche`s CEO Severin Schwan said: "I am pleased to appoint James Sabry as Global Head of Partnering.
OTCQX: RHHBY) announced today the result of a collaboration with the University of Missouri School of Medicine (MU School of Medicine) to implement—for the first time in the U.S.—Roche's new software solution to streamline and standardize the management of tumor boards, or multi-disciplinary meetings oncology care teams hold to make clinical treatment decisions for cancer patients.
OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced they have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share in cash. This corresponds to a total transaction value of US$ 2.4 billion on a fully diluted basis, and a total company value of US$ 5.3 billion on a fully diluted basis.
After a follow-up time of nearly five years the CLL11 study shows a 51% reduction in the risk of disease progression or death with Gazyva/Gazyvaro compared to MabThera/Rituxan The final analysis reports ...
OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data will be presented at the 4th Congress of the European Academy of Neurology (EAN) from June 16-19 in Lisbon, Portugal. The new Phase III data analyses show OCREVUS may provide meaningful disability benefits such as delay in the need for a wheelchair for people with primary progressive multiple sclerosis (PPMS). Genentech continues its commitment to people with progressive forms of MS by initiating two new global Phase IIIb studies that will evaluate the efficacy of OCREVUS in a broad range of people with progressive forms of MS.
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
CoaguChek® Vantus system enables wireless reporting of INR results, making it easier for patients to accurately report their results. OTCQX: RHHBY) announced today plans to launch the CoaguChek Vantus system, the first self-testing device for coagulation monitoring with built in Bluetooth technology. Patient self-testing with the Bluetooth-enabled CoaguChek Vantus system allows for a new level of patient monitoring.
OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group. “We are pleased that this approval makes Venclexta, a first of its kind targeted therapy, available for more people with chronic lymphocytic leukemia whose disease has returned after previous treatment,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development.
Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration has approved Rituxan® for the trea
-- CT/NG test, cobas omni Utility Channel offer IVD, LDT menu consolidation options for fully automated cobas 6800/8800 platform -- Micro Insights Theater to feature 30-minute briefings on key microbiology ...
OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for HEMLIBRA® (emicizumab-kxwh) for adults and children with hemophilia A without factor VIII inhibitors. The FDA is expected to make a decision on approval by October 4, 2018. “People with hemophilia A can face significant challenges in managing their condition and may need to adapt their daily lives to avoid bleeds and accommodate treatment,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development.
The 12-month PFS rate was doubled for people who received the TECENTRIQ combination (24.7 percent) compared to those who received chemotherapy alone (12.0 percent). A statistically significant overall survival (OS) benefit was not observed at the interim analysis, and the study will continue as planned.
Genentech, a member of the Roche Group , today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival and progression-free survival .
Genentech, a member of the Roche Group , announced today full results from the Phase III HAVEN 3 study evaluating HEMLIBRA® prophylaxis administered every week or every two weeks in people with hemophilia A without factor VIII inhibitors and the Phase III HAVEN 4 study evaluating HEMLIBRA prophylaxis administered every four weeks in people with hemophilia A with or without factor VIII inhibitors.
Genentech, a member of the Roche Group , today announced follow-up data from the Phase III ALEX study, showing that as an initial treatment Alecensa® significantly reduced the risk of disease progression or death by 57 percent compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase -positive metastatic non-small cell lung cancer , as assessed by the investigator....
OTCQX: RHHBY), today announced positive results from the Phase III IMpower150 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration has approved the subcutaneous formulation of Actemra® for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older.
OTCQX: RHHBY), announced today that Phase III results for HEMLIBRA® (emicizumab-kxwh) will be presented for the first time during the World Federation of Hemophilia (WFH) 2018 World Congress from May 20-24 in Glasgow, Scotland. The late-breaking presentations include positive results from the pivotal HAVEN 3 study of HEMLIBRA dosed every week or every two weeks in people with hemophilia A without factor VIII inhibitors and the pivotal HAVEN 4 study of HEMLIBRA dosed every four weeks in people with hemophilia A with or without factor VIII inhibitors.
OTCQX: RHHBY) announced today FDA approval of an additional claim for the cobas® Zika test for use on the cobas® 6800/8800 Systems. The newly approved claim allows for the streamlined screening of multiple individual blood or plasma donations that have been pooled together.
OTCQX: RHHBY), today announced that the Phase III IMblaze370 study evaluating the combination of TECENTRIQ® (atezolizumab) and COTELLIC® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intolerant to at least two systemic chemotherapy regimens. The results from IMblaze370 were consistent with this prior monotherapy experience, showing that treatment with TECENTRIQ alone did not provide a meaningful clinical benefit compared to regorafenib in this patient population.
Genentech, a member of the Roche Group , today announced that new data from early and late-stage clinical studies on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of Clinical Oncology Annual Meeting, taking place from June 1-5 in Chicago.
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). The FDA is expected to make a decision on approval by September 5, 2018.
INDIANAPOLIS, May 1, 2018 /PRNewswire/ -- Roche Diabetes Care today announced the launch of #BuckOffDiabetes, a campaign that represents a bold, new attitude for taking on diabetes. With the Accu-Chek® Guide SimplePay Programi people with diabetes can save a few bucks by always paying the same low price for every test strip refill. Furthermore, Roche Diabetes Care is asking everyone to get involved. Whether you have diabetes, or if diabetes affects someone you know and love, you can join the movement by turning your hand into bull horns and sharing a photo on social media with #BuckOffDiabetes.
OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from April 21-27 in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple sclerosis (RMS) through several measures of underlying disease activity and disability progression, including magnetic resonance imaging (MRI), cognitive function, and spinal fluid biomarkers of inflammation and neurodegeneration. New safety data remain consistent with OCREVUS’ favorable benefit-risk profile in both relapsing and primary progressive multiple sclerosis (PPMS).
- New indication as a companion diagnostic with AstraZeneca's TAGRISSO® (osimertinib) in first line treatment of patients with non-small cell lung cancer (NSCLC) - Results for EGFR mutations can be available ...